West Pharmaceutical
713 hedge funds and large institutions have $15.6B invested in West Pharmaceutical in 2025 Q1 according to their latest regulatory filings, with 91 funds opening new positions, 273 increasing their positions, 262 reducing their positions, and 114 closing their positions.
56% more call options, than puts
Call options by funds: $98M | Put options by funds: $63M
4% more repeat investments, than reductions
Existing positions increased: 273 | Existing positions reduced: 262
0.21% more ownership
Funds ownership: 96.43% → 96.64% (+0.21%)
5% less funds holding
Funds holding: 747 → 713 (-34)
20% less first-time investments, than exits
New positions opened: 91 | Existing positions closed: 114
32% less capital invested
Capital invested by funds: $22.9B → $15.6B (-$7.25B)
70% less funds holding in top 10
Funds holding in top 10: 10 → 3 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCP
Durable Capital Partners
Bethesda,
Maryland
|
+$258M |
| 2 |
VanEck Associates
New York
|
+$209M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
+$197M |
| 4 |
Two Sigma Investments
New York
|
+$123M |
| 5 |
Gates Foundation Trust
Kirkland,
Washington
|
+$123M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$692M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$252M |
| 3 |
BlackRock
New York
|
-$143M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$108M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$102M |
WST Hedge Fund Activity: Q1 2025 in Review
713 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q1 2025, worth a combined $15.6B — down 32% from $22.9B a quarter earlier.
Sellers outnumbered buyers: 114 funds closed out of WST and 91 opened new positions — a net loss of 23 holders — while 262 trimmed existing stakes and 273 added.
The largest buyer was Durable Capital Partners, adding an estimated $258M. The largest seller was AllianceBernstein, cutting an estimated $692M.
- 713 institutional investors held West Pharmaceutical (WST) as of Q1 2025, down from 747 in Q4 2024.
- Funds reported $15.6B of West Pharmaceutical stock for Q1 2025, down 32% quarter-over-quarter.
- 91 funds opened new West Pharmaceutical positions in Q1 2025 and 114 closed out, a net change of -23 holders.
- The largest West Pharmaceutical buyer in Q1 2025 was Durable Capital Partners, an estimated $258M added.
- The largest West Pharmaceutical seller in Q1 2025 was AllianceBernstein, an estimated $692M sold.
Based on aggregated 13F filings for Q1 2025.